RT Journal Article
T1 Neutrophil ß1 adrenoceptor blockade blunts stroke-associated neuroinflammation
A1 Clemente-Moragón, Agustín
A1 Oliver, Eduardo
A1 Calle, Daniel
A1 Cusso Mula, Lorena
A1 Gómez, Mónica
A1 Pradillo, Jesús M.
A1 Castejón, Raquel
A1 Rallón, Norma
A1 Benito, José M.
A1 Fernández-Ferro, José C.
A1 Carneado-Ruiz, Joaquín
A1 Moro, María A.
A1 Sánchez-González, Javier
A1 Fuster, Valentín
A1 Cortés-Canteli, Marta
A1 Desco Menéndez, Manuel
A1 Ibáñez, Borja
AB Background and Purpose: Reperfusion therapy is the standard of care for ischaemic stroke; however, there is a need to identify new therapeutic targets able to ameliorate cerebral damage. Neutrophil β1 adrenoceptors (β1AR) have been linked to neutrophil migration during exacerbated inflammation. Given the central role of neutrophils in cerebral damage during stroke, we hypothesize that β1AR blockade will improve stroke outcomes.Experimental Approach: Rats were subjected to middle cerebral artery occlusion–reperfusion to evaluate the effect on stroke of the selective β1AR blocker metoprolol (12.5 mg·kg−1) when injected i.v. 10 min before reperfusion.Key Results: Magnetic resonance imaging and histopathology analysis showed that pre-reperfusion i.v. metoprolol reduced infarct size. This effect was accompanied by reduced cytotoxic oedema at 24 h and vasogenic oedema at 7 days. Metoprolol-treated rats showed reduced brain neutrophil infiltration and those which infiltrated displayed a high proportion of anti-inflammatory phenotype (N2, YM1+). Additional inflammatory models demonstrated that metoprolol specifically blocked neutrophil migration via β1AR and excluded a significant effect on the glia compartment. Consistently, metoprolol did not protect the brain in neutrophil-depleted rats upon stroke. In patients suffering an ischaemic stroke, β1AR blockade by metoprolol reduced circulating neutrophil–platelet co-aggregates.Conclusions and Implications: Our findings describe that β1AR blockade ameliorates cerebral damage by targeting neutrophils, identifying a novel therapeutic target to improve outcomes in patients with stroke. This therapeutic strategy is in the earliest stages of the translational pathway and should be further explored.
PB Wiley
SN 0007-1188
YR 2023
FD 2023-02
LK https://hdl.handle.net/10016/37381
UL https://hdl.handle.net/10016/37381
LA eng
NO This study received funding from the Instituto de Salud Carlos III (ISCIII; PI16/02110 to B.I. and PT20/00044 to M.D.), the European Regional Development Fund (ERDF) "A way of making Europe" the Comunidad de Madrid (S2017/BMD-3867 RENIM-CM to M.D. and B.I.), cofunding from European structural, and investment funds, and by Agencia Estatal de Investigación (PID2019-110369RB-I00 to B.I.). B.I. is a recipient of funding from the European Research Council (ERC) under the European Union Horizon 2020 Research and Innovation Programme (ERC-Consolidator Grant agreement No. 819775). E.O. is a recipient of funds from the Comunidad de Madrid Programa de Atracción de Talento (2017-T1/BMD-5185) and from a Ramón y Cajal grant (RYC2020-028884-I) funded by MCIN/AEI/10.13039/501100011033 and by "ESF Investing in your future." A.C.M. is the beneficiary of an FPU fellowship from the Ministerio de Ciencia e Innovación (FPU2017/01932). M.C.C. is the beneficiary of a Miguel Servet contract (MS16/00174). The CNIC is supported by the ISCIII, the Ministerio de Ciencia e Innovación and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S).
DS e-Archivo
RD 1 sept. 2024